Download PDF
Semin Neurol 2019; 39(05): 651-668
DOI: 10.1055/s-0039-1688989
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neuropathy of Connective Tissue Diseases and Other Systemic Diseases

Peter H. Jin
1   Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York
,
Susan C. Shin
1   Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
22 October 2019 (online)

    Permissions and Reprints

Abstract

Peripheral neuropathy is associated with numerous systemic diseases. It is often the heralding finding, which can lead to earlier diagnoses and better outcomes. An understanding of the epidemiology and clinical features of these diseases is paramount to their diagnosis and management. This article will focus on neuropathy associated with connective tissue diseases, monoclonal gammopathies, paraneoplastic disorders, medications including chemotherapeutic agents, nutritional deficiencies, alcohol, and toxins.

Keywords

systemic disease - peripheral neuropathy - chemotherapy - nutrition - toxins

Financial disclosure

None.


 

  • References

  • 1 Petri M, Orbai A-M, Alarcón GS. , et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64 (08) 2677-2686
    CrossrefPubMedGoogle Scholar
  • 2 Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Systemic lupus erythematosus, rheumatoid arthritis, and other connective tissue diseases. In: Harrison's Manual of Medicine. 19th ed. New York, NY: McGraw-Hill Education; 2016: 843-849
    Google Scholar
  • 3 Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2011; 41 (02) 203-211
    CrossrefPubMedGoogle Scholar
  • 4 Xianbin W, Mingyu W, Dong X. , et al. Peripheral neuropathies due to systemic lupus erythematosus in China. Medicine (Baltimore) 2015; 94 (11) e625
    PubMedGoogle Scholar
  • 5 Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L. , et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64 (04) 620-625
    CrossrefPubMedGoogle Scholar
  • 6 Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 2015; 13 (01) 43
    CrossrefPubMedGoogle Scholar
  • 7 Tavee JO, Stern BJ. Neurosarcoidosis. Continuum (Minneap Minn) 2014; 20 (3 Neurology of Systemic Disease): 545-559
    PubMedGoogle Scholar
  • 8 Said G, Lacroix C, Planté-Bordeneuve V. , et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain 2002; 125 (Pt 2): 264-275
    CrossrefPubMedGoogle Scholar
  • 9 Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med 2017; 126: 135-138
    CrossrefPubMedGoogle Scholar
  • 10 Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105 (01) 101-105
    CrossrefPubMedGoogle Scholar
  • 11 Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011; 15 (03) 201-206
    CrossrefPubMedGoogle Scholar
  • 12 Heij L, Niesters M, Swartjes M. , et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012; 18 (01) 1430-1436
    CrossrefPubMedGoogle Scholar
  • 13 Brines M, Dunne AN, van Velzen M. , et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015; 20 (01) 658-666
    PubMedGoogle Scholar
  • 14 Dahan A, Dunne A, Swartjes M. , et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013; 19 (01) 334-345
    CrossrefPubMedGoogle Scholar
  • 15 Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology 1991; 41 (10) 1558-1561
    CrossrefPubMedGoogle Scholar
  • 16 Vitali C, Bombardieri S, Jonsson R. , et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61 (06) 554-558
    CrossrefPubMedGoogle Scholar
  • 17 Grant IA, Hunder GG, Homburger HA, Dyck PJ. Peripheral neuropathy associated with sicca complex. Neurology 1997; 48 (04) 855-862
    CrossrefPubMedGoogle Scholar
  • 18 Morozumi S, Kawagashira Y, Iijima M. , et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. J Neurol Sci 2009; 279 (1–2): 57-61
    CrossrefPubMedGoogle Scholar
  • 19 Pavlakis PP, Alexopoulos H, Kosmidis ML. , et al. Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012; 39 (1–2): 27-33
    CrossrefPubMedGoogle Scholar
  • 20 Dimberg EL. Rheumatology and neurology. Continuum (Minneap Minn) 2017; 23 (3, Neurology of Systemic Disease): 691-721
    PubMedGoogle Scholar
  • 21 Agarwal V, Singh R. , Wiclaf, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol 2008; 27 (07) 841-844
    CrossrefPubMedGoogle Scholar
  • 22 Puéchal X, Said G, Hilliquin P. , et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995; 38 (11) 1618-1629
    CrossrefPubMedGoogle Scholar
  • 23 Good AE, Christopher RP, Koepke GH, Bender LF, Tarter ME. Peripheral neuropathy associated with rheumatoid arthritis: a clinical and electrodiagnostic study of 70 consecutive rheumatoid arthritis patients. Ann Intern Med 1965; 63 (01) 87-99
    PubMedGoogle Scholar
  • 24 Poncelet AN, Connolly MK. Peripheral neuropathy in scleroderma. Muscle Nerve 2003; 28 (03) 330-335
    CrossrefPubMedGoogle Scholar
  • 25 Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 2013; 43 (03) 335-347
    CrossrefPubMedGoogle Scholar
  • 26 Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc 2017; 92 (05) 838-850
    CrossrefPubMedGoogle Scholar
  • 27 Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep 2012; 12 (01) 102-110
    CrossrefPubMedGoogle Scholar
  • 28 Rögnvaldsson S, Steingrímsson V, Turesson I, Björkholm M, Landgren O, Kristinsson SY. Peripheral neuropathy is an under-recognized feature of monoclonal gammopathy of undetermined significance: a population-based study of 18,668 MGUS patients and their 97,641 matched controls. Blood 2017; 130 (Suppl. 01) 4338
    PubMedGoogle Scholar
  • 29 Mauermann ML. Neurologic complications of lymphoma, leukemia, and paraproteinemias. Continuum (Minneap Minn) 2017; 23 (3, Neurology of Systemic Disease): 669-690
    PubMedGoogle Scholar
  • 30 Kim H, Lim Y-M, Jin JY. , et al. Electrophysiologic features of POEMS syndrome compared with MGUS-related neuropathy. Muscle Nerve 2017; 56 (06) E73-E77
    CrossrefPubMedGoogle Scholar
  • 31 Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 2010; 15 (03) 185-195
    CrossrefPubMedGoogle Scholar
  • 32 Campagnolo M, Zambello R, Nobile-Orazio E. , et al. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. J Neurol Neurosurg Psychiatry 2017; 88 (12) 1094-1097
    CrossrefPubMedGoogle Scholar
  • 33 Muppidi S, Vernino S. Paraneoplastic neuropathies. Continuum (Minneap Minn) 2014; 20 (5 Peripheral Nervous System Disorders): 1359-1372
    PubMedGoogle Scholar
  • 34 Koike H, Sobue G. Paraneoplastic neuropathy. Handb Clin Neurol 2013; 115: 713-726
    PubMedGoogle Scholar
  • 35 Graus F, Delattre JY, Antoine JC. , et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75 (08) 1135-1140
    CrossrefPubMedGoogle Scholar
  • 36 Giometto B, Grisold A, Grisold W. Paraneoplastic diseases of the peripheral nervous system. In: Angelini C. , ed. Acquired Neuromuscular Disorders. Cham: Springer International Publishing; 2016: 231-241
    Google Scholar
  • 37 Distad BJ, Weiss MD. Paraneoplastic motor neuron disease associated with Purkinje cell autoantibody type 1. J Clin Neuromuscul Dis 2010; 12 (01) 36-41
    CrossrefPubMedGoogle Scholar
  • 38 Samarasekera S, Rajabally YA. Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy. Muscle Nerve 2011; 43 (05) 764-766
    CrossrefPubMedGoogle Scholar
  • 39 Neal AJ, Qian MY, Clinch AS, Le BH. Orthostatic hypotension secondary to CRMP-5 paraneoplastic autonomic neuropathy. J Clin Neurosci 2014; 21 (05) 885-886
    CrossrefPubMedGoogle Scholar
  • 40 Giometto B, Vitaliani R, Lindeck-Pozza E, Grisold W, Vedeler C. Treatment for paraneoplastic neuropathies. Cochrane Database Syst Rev 2012; 12: CD007625
    PubMedGoogle Scholar
  • 41 Graus F, Dalmau J. Paraneoplastic neuropathies. Curr Opin Neurol 2013; 26 (05) 489-495
    CrossrefPubMedGoogle Scholar
  • 42 Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000; 68 (06) 750-755
    CrossrefPubMedGoogle Scholar
  • 43 Misiunas A, Niepomniszcze H, Ravera B, Faraj G, Faure E. Peripheral neuropathy in subclinical hypothyroidism. Thyroid 1995; 5 (04) 283-286
    CrossrefPubMedGoogle Scholar
  • 44 Khedr EM, El Toony LF, Tarkhan MN, Abdella G. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology 2000; 41 (02) 88-94
    CrossrefPubMedGoogle Scholar
  • 45 Karne SS, Bhalerao NS. Carpal tunnel syndrome in hypothyroidism. J Clin Diagn Res 2016; 10 (02) OC36-OC38
    PubMedGoogle Scholar
  • 46 Khan S, Zhou L. Characterization of non-length-dependent small-fiber sensory neuropathy. Muscle Nerve 2012; 45 (01) 86-91
    CrossrefPubMedGoogle Scholar
  • 47 Ørstavik K, Norheim I, Jørum E. Pain and small-fiber neuropathy in patients with hypothyroidism. Neurology 2006; 67 (05) 786-791
    CrossrefPubMedGoogle Scholar
  • 48 Nebuchennykh M, Løseth S, Lindal S, Mellgren SI. The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy. J Neurol 2009; 256 (07) 1067-1075
    CrossrefPubMedGoogle Scholar
  • 49 Kececi H, Degirmenci Y. Hormone replacement therapy in hypothyroidism and nerve conduction study. Neurophysiol Clin 2006; 36 (02) 79-83
    CrossrefPubMedGoogle Scholar
  • 50 El-Salem K, Ammari F. Neurophysiological changes in neurologically asymptomatic hypothyroid patients: a prospective cohort study. J Clin Neurophysiol 2006; 23 (06) 568-572
    CrossrefPubMedGoogle Scholar
  • 51 Sözay S, Gökçe-Kutsal Y, Celiker R, Erbas T, Başgöze O. Neuroelectrophysiological evaluation of untreated hyperthyroid patients. Thyroidology (Pisa) 1994; 6 (02) 55-59
    PubMedGoogle Scholar
  • 52 Al-Wahaibi AK, Kumar S, Al-Risi A, Wali F. Thyrotoxic neuropathy: a rare cause of acute flaccid paraplegia. Sultan Qaboos Univ Med J 2017; 17 (04) e460-e463
    PubMedGoogle Scholar
  • 53 Pandit L, Shankar SK, Gayathri N, Pandit A. Acute thyrotoxic neuropathy--Basedow's paraplegia revisited. J Neurol Sci 1998; 155 (02) 211-214
    CrossrefPubMedGoogle Scholar
  • 54 Knill-Jones RP, Goodwill CJ, Dayan AD, Williams R. Peripheral neuropathy in chronic liver disease: clinical, electrodiagnostic, and nerve biopsy findings. J Neurol Neurosurg Psychiatry 1972; 35 (01) 22-30
    CrossrefPubMedGoogle Scholar
  • 55 Campellone JV, Lacomis D, Giuliani MJ, Kramer DJ. Mononeuropathies associated with liver transplantation. Muscle Nerve 1998; 21 (07) 896-901
    CrossrefPubMedGoogle Scholar
  • 56 Wijdicks EFM, Litchy WJ, Wiesner RH, Krom RAF. Neuromuscular complications associated with liver transplantation. Muscle Nerve 1996; 19 (06) 696-700
    CrossrefPubMedGoogle Scholar
  • 57 Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007; 35 (03) 273-290
    CrossrefPubMedGoogle Scholar
  • 58 Thomas PK. Screening for peripheral neuropathy in patients treated by chronic hemodialysis. Muscle Nerve 1978; 1 (05) 396-399
    CrossrefPubMedGoogle Scholar
  • 59 Bolton CF. Peripheral neuropathies associated with chronic renal failure. Can J Neurol Sci 1980; 7 (02) 89-96
    PubMedGoogle Scholar
  • 60 Arnold R, Issar T, Krishnan AV, Pussell BA. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis 2016; 5: 2048004016677687
    PubMedGoogle Scholar
  • 61 Halar EM, Brozovich FV, Milutinovic J, Inouye VL, Becker VM. H-reflex latency in uremic neuropathy: correlation with NCV and clinical findings. Arch Phys Med Rehabil 1979; 60 (04) 174-177
    PubMedGoogle Scholar
  • 62 Nardin R, Chapman KM, Raynor EM. Prevalence of ulnar neuropathy in patients receiving hemodialysis. Arch Neurol 2005; 62 (02) 271-275
    CrossrefPubMedGoogle Scholar
  • 63 Delmez JA, Holtmann B, Sicard GA, Goldberg AP, Harter HR. Peripheral nerve entrapment syndromes in chronic hemodialysis patients. Nephron 1982; 30 (02) 118-123
    CrossrefPubMedGoogle Scholar
  • 64 Mambelli E, Barrella M, Facchini MG. , et al. The prevalence of peripheral neuropathy in hemodialysis patients. Clin Nephrol 2012; 77 (06) 468-475
    CrossrefPubMedGoogle Scholar
  • 65 Chao C-C, Wu V-C, Tan C-H. , et al. Skin denervation and its clinical significance in late-stage chronic kidney disease. Arch Neurol 2011; 68 (02) 200-206
    PubMedGoogle Scholar
  • 66 Bazzi C, Pagani C, Sorgato G, Albonico G, Fellin G, D'Amico G. Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients. Clin Nephrol 1991; 35 (04) 176-181
    PubMedGoogle Scholar
  • 67 Ogura T, Makinodan A, Kubo T, Hayashida T, Hirasawa Y. Electrophysiological course of uraemic neuropathy in haemodialysis patients. Postgrad Med J 2001; 77 (909) 451-454
    CrossrefPubMedGoogle Scholar
  • 68 Ho DT, Rodig NM, Kim HB. , et al. Rapid reversal of uremic neuropathy following renal transplantation in an adolescent. Pediatr Transplant 2012; 16 (07) E296-E300
    CrossrefPubMedGoogle Scholar
  • 69 Bolton CF. Electrophysiologic changes in uremic neuropathy after successful renal transplantation. Neurology 1976; 26 (02) 152-161
    CrossrefPubMedGoogle Scholar
  • 70 Zochodne DW, Bolton CF, Wells GA. , et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain 1987; 110 (Pt 4): 819-841
    CrossrefPubMedGoogle Scholar
  • 71 Shepherd S, Batra A, Lerner DP. Review of critical illness myopathy and neuropathy. Neurohospitalist 2017; 7 (01) 41-48
    PubMedGoogle Scholar
  • 72 Amato AA, Russell JA. Neuromuscular Disorders. 2nd ed. New York, NY: McGraw-Hill Education; 2015
    Google Scholar
  • 73 Zifko UA, Zipko HT, Bolton CF. Clinical and electrophysiological findings in critical illness polyneuropathy. J Neurol Sci 1998; 159 (02) 186-193
    CrossrefPubMedGoogle Scholar
  • 74 Brunner R, Rinner W, Haberler C. , et al. Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial. Crit Care 2013; 17 (05) R213
    CrossrefPubMedGoogle Scholar
  • 75 Cunningham CJB, Finlayson HC, Henderson WR, O'Connor RJ, Travlos A. Impact of critical illness polyneuromyopathy in rehabilitation: a prospective observational study. PM R 2018; 10 (05) 494-500
    CrossrefPubMedGoogle Scholar
  • 76 Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry 2008; 79 (07) 838-841
    CrossrefPubMedGoogle Scholar
  • 77 Intiso D, Amoruso L, Zarrelli M. , et al. Long-term functional outcome and health status of patients with critical illness polyneuromyopathy. Acta Neurol Scand 2011; 123 (03) 211-219
    PubMedGoogle Scholar
  • 78 Koch S, Wollersheim T, Bierbrauer J. , et al. Long-term recovery In critical illness myopathy is complete, contrary to polyneuropathy. Muscle Nerve 2014; 50 (03) 431-436
    CrossrefPubMedGoogle Scholar
  • 79 Postma TJ, Heimans JJ. Neurological complications of chemotherapy to the peripheral nervous system. Handb Clin Neurol 2012; 105: 917-936
    PubMedGoogle Scholar
  • 80 Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncol 2012; 14 (Suppl. 04) iv45-iv54
    PubMedGoogle Scholar
  • 81 Pachman DR, Loprinzi CL, Grothey A, Ta LE. The search for treatments to reduce chemotherapy-induced peripheral neuropathy. J Clin Invest 2014; 124 (01) 72-74
    CrossrefPubMedGoogle Scholar
  • 82 Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014; 31 (03) CD005228
    PubMedGoogle Scholar
  • 83 McLeod JG, Penny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1969; 32 (04) 297-304
    CrossrefPubMedGoogle Scholar
  • 84 Verstappen CCP, Koeppen S, Heimans JJ. , et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64 (06) 1076-1077
    CrossrefPubMedGoogle Scholar
  • 85 Diouf B, Crews KR, Lew G. , et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 2015; 313 (08) 815-823
    CrossrefPubMedGoogle Scholar
  • 86 Stock W, Diouf B, Crews KR. , et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther 2017; 101 (03) 391-395
    PubMedGoogle Scholar
  • 87 Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 2014; 40 (07) 872-882
    CrossrefPubMedGoogle Scholar
  • 88 Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20 (07) 1767-1774
    CrossrefPubMedGoogle Scholar
  • 89 Duggett NA, Griffiths LA, Flatters SJL. Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons. Pain 2017; 158 (08) 1499-1508
    CrossrefPubMedGoogle Scholar
  • 90 Rampen AJJ, Jongen JLM, van Heuvel I, Scheltens-de Boer M, Sonneveld P, van den Bent MJ. Bortezomib-induced polyneuropathy. Neth J Med 2013; 71 (03) 128-133
    PubMedGoogle Scholar
  • 91 Bechakra M, Nieuwenhoff MD, van Rosmalen J. , et al. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Mol Pain 2018; 14: 1744806918797042
    PubMedGoogle Scholar
  • 92 Richardson PG, Sonneveld P, Schuster MW. , et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009; 144 (06) 895-903
    CrossrefPubMedGoogle Scholar
  • 93 Fellner A, Makranz C, Lotem M. , et al. Neurologic complications of immune checkpoint inhibitors. J Neurooncol 2018; 137 (03) 601-609
    CrossrefPubMedGoogle Scholar
  • 94 Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29 (06) 806-812
    CrossrefPubMedGoogle Scholar
  • 95 Thaipisuttikul I, Chapman P, Avila EK. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother 2015; 38 (02) 77-79
    CrossrefPubMedGoogle Scholar
  • 96 Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017; 8: 49
    CrossrefPubMedGoogle Scholar
  • 97 American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers, 2011–2017. Available at: https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers . Accessed May 1, 2019
    PubMedGoogle Scholar
  • 98 Levinson R, Silverman JB, Catella JG, Rybak I, Jolin H, Isom K. Pharmacotherapy prevention and management of nutritional deficiencies post Roux-en-Y gastric bypass. Obes Surg 2013; 23 (07) 992-1000
    CrossrefPubMedGoogle Scholar
  • 99 Tack J, Deloose E. Complications of bariatric surgery: dumping syndrome, reflux and vitamin deficiencies. Best Pract Res Clin Gastroenterol 2014; 28 (04) 741-749
    PubMedGoogle Scholar
  • 100 Kumar N. Neurologic presentations of nutritional deficiencies. Neurol Clin 2010; 28 (01) 107-170
    CrossrefPubMedGoogle Scholar
  • 101 Koike H, Iijima M, Sugiura M. , et al. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol 2003; 54 (01) 19-29
    CrossrefPubMedGoogle Scholar
  • 102 Koike H, Ito S, Morozumi S. , et al. Rapidly developing weakness mimicking Guillain-Barré syndrome in beriberi neuropathy: two case reports. Nutrition 2008; 24 (7-8): 776-780
    CrossrefPubMedGoogle Scholar
  • 103 Faigle R, Mohme M, Levy M. Dry beriberi mimicking Guillain-Barre syndrome as the first presenting sign of thiamine deficiency. Eur J Neurol 2012; 19 (02) e14-e15
    CrossrefPubMedGoogle Scholar
  • 104 Hamel J, Logigian EL. Acute nutritional axonal neuropathy. Muscle Nerve 2018; 57 (01) 33-39
    CrossrefPubMedGoogle Scholar
  • 105 McCombe PA, McLeod JG. The peripheral neuropathy of vitamin B12 deficiency. J Neurol Sci 1984; 66 (01) 117-126
    CrossrefPubMedGoogle Scholar
  • 106 Fine EJ, Soria E, Paroski MW, Petryk D, Thomasula L. The neurophysiological profile of vitamin B12 deficiency. Muscle Nerve 1990; 13 (02) 158-164
    CrossrefPubMedGoogle Scholar
  • 107 Kalita J, Chandra S, Bhoi SK. , et al. Clinical, nerve conduction and nerve biopsy study in vitamin B12 deficiency neurological syndrome with a short-term follow-up. Nutr Neurosci 2014; 17 (04) 156-163
    CrossrefPubMedGoogle Scholar
  • 108 Staff NP, Windebank AJ. Peripheral neuropathy due to vitamin deficiency, toxins, and medications. Continuum (Minneap Minn) 2014; 20 (5 Peripheral Nervous System Disorders): 1293-1306
    PubMedGoogle Scholar
  • 109 Koike H, Takahashi M, Ohyama K. , et al. Clinicopathologic features of folate-deficiency neuropathy. Neurology 2015; 84 (10) 1026-1033
    CrossrefPubMedGoogle Scholar
  • 110 Hammond N, Wang Y, Dimachkie MM, Barohn RJ. Nutritional neuropathies. Neurol Clin 2013; 31 (02) 477-489
    CrossrefPubMedGoogle Scholar
  • 111 Bakkers M, Faber CG, Hoeijmakers JGJ, Lauria G, Merkies ISJ. Small fibers, large impact: quality of life in small-fiber neuropathy. Muscle Nerve 2014; 49 (03) 329-336
    CrossrefPubMedGoogle Scholar
  • 112 Kulkantrakorn K. Pyridoxine-induced sensory ataxic neuronopathy and neuropathy: revisited. Neurol Sci 2014; 35 (11) 1827-1830
    CrossrefPubMedGoogle Scholar
  • 113 Traber MG, Sokol RJ, Ringel SP, Neville HE, Thellman CA, Kayden HJ. Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. N Engl J Med 1987; 317 (05) 262-265
    CrossrefPubMedGoogle Scholar
  • 114 Duncan A, Yacoubian C, Watson N, Morrison I. The risk of copper deficiency in patients prescribed zinc supplements. J Clin Pathol 2015; 68 (09) 723-725
    CrossrefPubMedGoogle Scholar
  • 115 Coyle L, Entezaralmahdi M, Adeola M, De Hoyos P, Mehed A, Varon J. The perfect storm: copper deficiency presenting as progressive peripheral neuropathy. Am J Emerg Med 2016; 34 (02) 340.e5-340.e6
    CrossrefPubMedGoogle Scholar
  • 116 Walsh JC, McLeod JG. Alcoholic neuropathy. An electrophysiological and histological study. J Neurol Sci 1970; 10 (05) 457-469
    CrossrefPubMedGoogle Scholar
  • 117 Koike H, Sobue G. Alcoholic neuropathy. Curr Opin Neurol 2006; 19 (05) 481-486
    CrossrefPubMedGoogle Scholar
  • 118 Johnson RH, Robinson BJ. Mortality in alcoholics with autonomic neuropathy. J Neurol Neurosurg Psychiatry 1988; 51 (04) 476-480
    CrossrefPubMedGoogle Scholar
  • 119 Guo YP, McLeod JG, Baverstock J. Pathological changes in the vagus nerve in diabetes and chronic alcoholism. J Neurol Neurosurg Psychiatry 1987; 50 (11) 1449-1453
    CrossrefPubMedGoogle Scholar
  • 120 Tan ET, Johnson RH, Lambie DG, Whiteside EA. Alcoholic vagal neuropathy: recovery following prolonged abstinence. J Neurol Neurosurg Psychiatry 1984; 47 (12) 1335-1337
    CrossrefPubMedGoogle Scholar
  • 121 Shorvon SD, Reynolds EH. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J Neurol Neurosurg Psychiatry 1982; 45 (07) 620-626
    CrossrefPubMedGoogle Scholar
  • 122 Ramirez JA, Mendell JR, Warmolts JR, Griggs RC. Phenytoin neuropathy: structural changes in the sural nerve. Ann Neurol 1986; 19 (02) 162-167
    CrossrefPubMedGoogle Scholar
  • 123 Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008; 23 (13) 1850-1859
    CrossrefPubMedGoogle Scholar
  • 124 Müller T, van Laar T, Cornblath DR. , et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013; 19 (05) 501-507 , discussion 501
    CrossrefPubMedGoogle Scholar
  • 125 Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol 2016; 23 (03) 501-509
    CrossrefPubMedGoogle Scholar
  • 126 Ceravolo R, Cossu G, Bandettini di Poggio M. , et al. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord 2013; 28 (10) 1391-1397
    CrossrefPubMedGoogle Scholar
  • 127 Stone SL, Cartwright MS, Panea OR, Vann RC, Magruder JL, Walker FO. Neuromuscular ultrasound findings in polyneuropathy secondary to disulfiram. J Clin Neurophysiol 2014; 31 (06) e18-e20
    CrossrefPubMedGoogle Scholar
  • 128 Mokri B, Ohnishi A, Dyck PJ. Disulfiram neuropathy. Neurology 1981; 31 (06) 730-735
    CrossrefPubMedGoogle Scholar
  • 129 Ansbacher LE, Bosch EP, Cancilla PA. Disulfiram neuropathy: a neurofilamentous distal axonopathy. Neurology 1982; 32 (04) 424-428
    CrossrefPubMedGoogle Scholar
  • 130 Johnston SR, Burn D, Brooks DJ. Peripheral neuropathy associated with lithium toxicity. J Neurol Neurosurg Psychiatry 1991; 54 (11) 1019-1020
    CrossrefPubMedGoogle Scholar
  • 131 Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol 2005; 28 (01) 38-49
    CrossrefPubMedGoogle Scholar
  • 132 Pamphlett RS, Mackenzie RA. Severe peripheral neuropathy due to lithium intoxication. J Neurol Neurosurg Psychiatry 1982; 45 (07) 656
    CrossrefPubMedGoogle Scholar
  • 133 Layzer RB. Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet 1978; 2 (8102): 1227-1230
    PubMedGoogle Scholar
  • 134 Weimann J. Toxicity of nitrous oxide. Best Pract Res Clin Anaesthesiol 2003; 17 (01) 47-61
    PubMedGoogle Scholar
  • 135 Layzer RB, Fishman RA, Schafer JA. Neuropathy following abuse of nitrous oxide. Neurology 1978; 28 (05) 504-506
    CrossrefPubMedGoogle Scholar
  • 136 Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 2004; 24 (09) 1194-1203
    CrossrefPubMedGoogle Scholar
  • 137 Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97 (8A) 52C-60C
    PubMedGoogle Scholar
  • 138 Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 2014; 83 (14) 1261-1263
    CrossrefPubMedGoogle Scholar
  • 139 Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001; 35 (12) 1540-1547
    CrossrefPubMedGoogle Scholar
  • 140 Chao C-C, Sun H-Y, Chang Y-C, Hsieh S-T. Painful neuropathy with skin denervation after prolonged use of linezolid. J Neurol Neurosurg Psychiatry 2008; 79 (01) 97-99
    CrossrefPubMedGoogle Scholar
  • 141 Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005; 64 (05) 926-927
    CrossrefPubMedGoogle Scholar
  • 142 Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4 (08) 528-531
    CrossrefPubMedGoogle Scholar
  • 143 Legout L, Senneville E, Gomel JJ, Yazdanpanah Y, Mouton Y. Linezolid-induced neuropathy. Clin Infect Dis 2004; 38 (05) 767-768
    CrossrefPubMedGoogle Scholar
  • 144 Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents 2018; 51 (03) 319-325
    CrossrefPubMedGoogle Scholar
  • 145 Zivkovic SA, Lacomis D, Giuliani MJ. Sensory neuropathy associated with metronidazole: report of four cases and review of the literature. J Clin Neuromuscul Dis 2001; 3 (01) 8-12
    CrossrefPubMedGoogle Scholar
  • 146 Estes ML, Ewing-wilson D, Samuel Chou DM. , et al. Chloroquine neuromyotoxicity clinical and pathologic perspective. Am J Med 1987; 82 (03) 447-455
    CrossrefPubMedGoogle Scholar
  • 147 Tegnér R, Tomé FMS, Godeau P, Lhermitte F, Fardeau M. Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol 1988; 75 (03) 253-260
    CrossrefPubMedGoogle Scholar
  • 148 Parodia A, Regestab G, Reboraa A. Chloroquine-induced neuromyopathy. Report of a case. Dermatologica 1985; 171 (03) 203-205
    CrossrefPubMedGoogle Scholar
  • 149 Ahrens EM, Meckler RJ, Callen JP. Dapsone-induced peripheral neuropathy. Int J Dermatol 1986; 25 (05) 314-316
    CrossrefPubMedGoogle Scholar
  • 150 McCarty M. How clinically relevant is dapsone-related peripheral neuropathy?: an overview of available data with emphasis on clinical recognition. J Clin Aesthet Dermatol 2010; 3 (03) 19-21
    PubMedGoogle Scholar
  • 151 Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy--an axonal disease. Neurology 1976; 26 (6, Pt 1): 514-516
    CrossrefPubMedGoogle Scholar
  • 152 Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 2010; 24 (08) 655-667
    CrossrefPubMedGoogle Scholar
  • 153 Devadatta S, Gangadharam PR, Andrews RH. , et al. Peripheral neuritis due to isoniazid. Bull World Health Organ 1960; 23 (4–5): 587-598
    PubMedGoogle Scholar
  • 154 Ochoa J. Isoniazid neuropathy in man: quantitative electron microscope study. Brain 1970; 93 (04) 831-850
    CrossrefPubMedGoogle Scholar
  • 155 Choudhary CR, Kumari J, Advani M. Isoniazid induced early-onset of motor dominant neuropathy and treatment with high dose of pyridoxine. Indian J Tuberc 2018; 65 (02) 175-176
    PubMedGoogle Scholar
  • 156 Arsalan R, Sabzwari S. Isoniazid induced motor-dominant neuropathy. J Pak Med Assoc 2015; 65 (10) 1131-1133
    PubMedGoogle Scholar
  • 157 Takeuchi H, Takahashi M, Kang J. , et al. Ethambutol neurophathy: clinical and electroneuromyographic studies. Folia Psychiatr Neurol Jpn 1980; 34 (01) 45-55
    PubMedGoogle Scholar
  • 158 Toole JF, Gergen JA, Hayes DM, Felts JH. Neural effects of nitrofurantoin. Arch Neurol 1968; 18 (06) 680-687
    CrossrefPubMedGoogle Scholar
  • 159 Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012; 69 (02) 265-268
    CrossrefPubMedGoogle Scholar
  • 160 Kammire LD, Donofrio PD. Nitrofurantoin neuropathy: a forgotten adverse effect. Obstet Gynecol 2007; 110 (2, Pt 2, Supplement): 510-512
    CrossrefPubMedGoogle Scholar
  • 161 Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9 (02) 153-161
    PubMedGoogle Scholar
  • 162 Brew BJ, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS 2003; 17 (07) 1094-1096
    CrossrefPubMedGoogle Scholar
  • 163 Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19 (06) 481-494
    CrossrefPubMedGoogle Scholar
  • 164 Xue H-X, Fu W-Y, Cui H-D, Yang L-L, Zhang N, Zhao L-J. High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis. Neural Regen Res 2015; 10 (05) 814-818
    CrossrefPubMedGoogle Scholar
  • 165 Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59 (12) 1872-1875
    CrossrefPubMedGoogle Scholar
  • 166 Labate A, Morelli M, Palamara G, Pirritano D, Quattrone A. Tacrolimus-induced polyneuropathy after heart transplantation. Clin Neuropharmacol 2010; 33 (03) 161-162
    CrossrefPubMedGoogle Scholar
  • 167 Bhagavati S, Maccabee P, Muntean E, Sumrani NB. Chronic sensorimotor polyneuropathy associated with tacrolimus immunosuppression in renal transplant patients: case reports. Transplant Proc 2007; 39 (10) 3465-3467
    CrossrefPubMedGoogle Scholar
  • 168 Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004; 75 (06) 580-585
    PubMedGoogle Scholar
  • 169 Kho LK, Kermode AG. Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007; 14 (02) 179-181
    CrossrefPubMedGoogle Scholar
  • 170 Carulli MT, Davies UM. Peripheral neuropathy: an unwanted effect of leflunomide?. Rheumatology (Oxford) 2002; 41 (08) 952-953
    CrossrefPubMedGoogle Scholar
  • 171 Fraser AG, McQueen IN, Watt AH, Stephens MR. Peripheral neuropathy during longterm high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry 1985; 48 (06) 576-578
    CrossrefPubMedGoogle Scholar
  • 172 Pellissier JF, Pouget J, Cros D, De Victor B, Serratrice G, Toga M. Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study. J Neurol Sci 1984; 63 (02) 251-266
    CrossrefPubMedGoogle Scholar
  • 173 Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316 (25) 1562-1568
    CrossrefPubMedGoogle Scholar
  • 174 Chuang HY, Schwartz J, Tsai SY, Lee ML, Wang JD, Hu H. Vibration perception thresholds in workers with long term exposure to lead. Occup Environ Med 2000; 57 (09) 588-594
    CrossrefPubMedGoogle Scholar
  • 175 Thomson RM, Parry GJ. Neuropathies associated with excessive exposure to lead. Muscle Nerve 2006; 33 (06) 732-741
    CrossrefPubMedGoogle Scholar
  • 176 Rubens O, Logina I, Kravale I, Eglîte M, Donaghy M. Peripheral neuropathy in chronic occupational inorganic lead exposure: a clinical and electrophysiological study. J Neurol Neurosurg Psychiatry 2001; 71 (02) 200-204
    CrossrefPubMedGoogle Scholar
  • 177 Oh SJ. Electrophysiological profile in arsenic neuropathy. J Neurol Neurosurg Psychiatry 1991; 54 (12) 1103-1105
    CrossrefPubMedGoogle Scholar
  • 178 Murphy MJ, Lyon LW, Taylor JW. Subacute arsenic neuropathy: clinical and electrophysiological observations. J Neurol Neurosurg Psychiatry 1981; 44 (10) 896-900
    CrossrefPubMedGoogle Scholar
  • 179 Ikeda T, Takahashi K, Kabata T, Sakagoshi D, Tomita K, Yamada M. Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement. Muscle Nerve 2010; 42 (01) 140-143
    CrossrefPubMedGoogle Scholar
  • 180 Catalani S, Rizzetti MC, Padovani A, Apostoli P. Neurotoxicity of cobalt. Hum Exp Toxicol 2012; 31 (05) 421-437
    CrossrefPubMedGoogle Scholar
  • 181 Chu C-C, Huang C-C, Ryu S-J, Wu T-N. Chronic inorganic mercury induced peripheral neuropathy. Acta Neurol Scand 1998; 98 (06) 461-465
    CrossrefPubMedGoogle Scholar
  • 182 Levine SP, Cavender GD, Langolf GD, Albers JW. Elemental mercury exposure: peripheral neurotoxicity. Br J Ind Med 1982; 39 (02) 136-139
    PubMedGoogle Scholar
  • 183 Gobba F, Cavalleri F, Bontadi D, Torri P, Dainese R. Peripheral neuropathy in styrene-exposed workers. Scand J Work Environ Health 1995; 21 (06) 517-520
    CrossrefPubMedGoogle Scholar
  • 184 Murata K, Araki S, Yokoyama K. Assessment of the peripheral, central, and autonomic nervous system function in styrene workers. Am J Ind Med 1991; 20 (06) 775-784
    CrossrefPubMedGoogle Scholar
  • 185 Kuo H-C, Huang C-C, Tsai Y-T, Chu C-C, Hsieh S-T, Chu N-S. Acute painful neuropathy in thallium poisoning. Neurology 2005; 65 (02) 302-304
    CrossrefPubMedGoogle Scholar
  • 186 Dumitru D, Kalantri A. Electrophysiologic investigation of thallium poisoning. Muscle Nerve 1990; 13 (05) 433-437
    CrossrefPubMedGoogle Scholar
  • 187 Mitchell J, Weller RO, Evans H, Arai I, Daves Jr GD. Buckthorn neuropathy: effects of intraneural injection of Karwinskia humboldtiana toxins. Neuropathol Appl Neurobiol 1978; 4 (02) 85-97
    CrossrefPubMedGoogle Scholar
  • 188 Calderon-Gonzalez R, Rizzi-Hernandez H. Buckthorn polyneuropathy. N Engl J Med 1967; 277 (02) 69-71
    CrossrefPubMedGoogle Scholar
  • 189 Rollins YD, Filley CM, McNutt JT, Chahal S, Kleinschmidt-DeMasters BK. Fulminant ascending paralysis as a delayed sequela of diethylene glycol (Sterno) ingestion. Neurology 2002; 59 (09) 1460-1463
    CrossrefPubMedGoogle Scholar
  • 190 Sosa NR, Rodriguez GM, Schier JG, Sejvar JJ. Clinical, laboratory, diagnostic, and histopathologic features of diethylene glycol poisoning--Panama, 2006. Ann Emerg Med 2014; 64 (01) 38-47
    CrossrefPubMedGoogle Scholar
  • 191 Herskowitz A, Ishii N, Schaumburg H. N-hexane neuropathy. A syndrome occurring as a result of industrial exposure. N Engl J Med 1971; 285 (02) 82-85
    CrossrefPubMedGoogle Scholar
  • 192 Smith AG, Albers JW. n-Hexane neuropathy due to rubber cement sniffing. Muscle Nerve 1997; 20 (11) 1445-1450
    CrossrefPubMedGoogle Scholar
  • 193 Pennisi M, Malaguarnera G, Puglisi V, Vinciguerra L, Vacante M, Malaguarnera M. Neurotoxicity of acrylamide in exposed workers. Int J Environ Res Public Health 2013; 10 (09) 3843-3854
    CrossrefPubMedGoogle Scholar
  • 194 Kim H, Lee SG, Rhie J. Dermal and neural toxicity caused by acrylamide exposure in two Korean grouting workers: a case report. Ann Occup Environ Med 2017; 29 (01) 50
    CrossrefPubMedGoogle Scholar
  • 195 Aaserud O, Hommeren OJ, Tvedt B. , et al. Carbon disulfide exposure and neurotoxic sequelae among viscose rayon workers. Am J Ind Med 1990; 18 (01) 25-37
    CrossrefPubMedGoogle Scholar